FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics (FBLG) filed its Q3 2025 report showing higher expenses and a wider loss, alongside a going concern warning. For the quarter ended September 30, 2025, operating expenses rose to $5.0 million, driven by research and development of $2.8 million and general and administrative of $2.2 million. The company reported a net loss of $5.8 million for the quarter and $15.4 million for the nine months.
Cash and cash equivalents were $4.9 million, down from $14.0 million at year-end, with net cash used in operations of $13.2 million year-to-date. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company detailed its Standby Equity Purchase Agreement, under which it issued $15.0 million in short-term convertible notes in three tranches and may require the investor to purchase up to an additional $10.0 million of common stock, subject to conditions. During 2025, $9.7 million of notes converted into 13,059,270 shares; additional conversions occurred in October. Shares outstanding were 48,263,979 as of September 30, 2025, and 51,456,077 as of October 31, 2025.
FibroBiologics, Inc. received a notification from the Nasdaq Listing Qualifications Staff that it does not meet the Nasdaq Capital Market requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35.0 million. The notice does not immediately affect the trading of the company’s common stock, but gives the company a 180-calendar-day cure period to regain compliance by having MVLS close at $35.0 million or more for at least ten consecutive business days before February 2, 2026. If the company fails to regain compliance, Nasdaq will notify FibroBiologics that its securities are subject to delisting, and the company may seek an appeal, though there is no assurance an appeal would be granted. The company stated it will monitor MVLS and consider options to regain compliance and filed this report to publicly disclose receipt of the Nasdaq notice.